Bezuclastinib in Non-Advanced and Advanced Systemic Mastocytosis
April 3, 2025 • ISM Content Hub
In an interview conducted at the 2024 American Society of Hematology Annual Meeting in San Diego, California, Prithviraj Bose, MD, The University of Texas MD Anderson Cancer Center, Houston, Texas, discussed the safety and efficacy of bezuclastinib. This therapy is under investigation for patients with non-advanced systemic mastocytosis in the SUMMIT trial, which is ongoing. Bezuclastinib is well tolerated and highly active at a dose of 100 mg, and is also under investigation for the treatment of patients with advanced systemic mastocytosis in the APEX trial.
